A label that stopped the search: attributing a rising creatinine to contrast
Educational use only. Not clinically reviewed66-year-old man for Review of the written attribution, review of the competing explanations it did not exclude, withdrawal of continuing nephrotoxic exposures, reassessment, and handoff of an unresolved cause. About 60 simulated minutes.
What you will practise
- Treat the written label as a hypothesis rather than a finding.
- Review what the label did not exclude.
- Separate what controlled comparison shows from what a before-and-after rise shows.
- Distinguish a current picture from a partial recheck, and know what a trend does not settle.
- Transfer an open question with the search explicitly still open.
Review and sources
Not clinically reviewed. No clinician has signed this scenario.
- Davenport MS, Perazella MA, Yee J, Dillman JR, et al. Use of Intravenous Iodinated Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Radiology. 2020;294:660–668. doi:10.1148/radiol.2019192094. A consensus statement rather than a trial. It says the risk has been overstated because historic studies lacked adequate control groups; it does not claim contrast-induced injury never occurs, it retains a small group at genuine risk, and the record lists six published comments on it.
- Hinson JS, Ehmann MR, Fine DM, Fishman EK, et al. Risk of Acute Kidney Injury After Intravenous Contrast Media Administration. Annals of Emergency Medicine. 2017;69:577–586.e4. doi:10.1016/j.annemergmed.2016.11.021. Single-centre and retrospective. Clinicians chose who received contrast and could see the patient, so the sickest are the least likely to have received it; propensity matching narrows that confounding rather than removing it. Evidence against a strong causal claim, not proof of no effect.
- Nijssen EC, Rennenberg RJ, Nelemans PJ, Essers BA, et al. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING). The Lancet. 2017;389:1312–1322. doi:10.1016/S0140-6736(17)30057-0. Single-centre, open-label, elective procedures only, and it excluded an eGFR below 30 and previous dialysis, so it says nothing about the highest-risk patients. Non-inferiority is not equivalence, and the record lists eleven published comments.
Open Sim Lab is an educational simulator, not for clinical use. It is not a clinical decision-support tool, not a dosing calculator, and is not validated for any decision affecting a real patient.